Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on the development of allogeneic gamma delta (γδ) T cell therapies for the treatment of cancer. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on oncology indications, including hematologic malignancies and solid tumors. Its core value proposition centers on leveraging the unique biology of γδ T cells, which can recognize and kill tumor cells without reliance on human leukocyte antigen (HLA) matching, enabling off-the-shelf therapeutic applications.
Founded in 2014, Adicet Bio evolved from early academic research into γδ T cell immunology and translational oncology. The company advanced from preclinical research to multiple clinical-stage programs and became publicly traded in 2021. Adicet Bio positions itself as a differentiated player in cell therapy by focusing on engineered γδ T cells rather than conventional alpha beta T cell or CAR-T approaches, aiming to improve safety, scalability, and therapeutic reach.
Business Operations
Adicet Bio’s operations are organized around the research, development, and clinical advancement of its proprietary γδ T cell therapy platform. The company’s lead clinical programs include ADI-001, targeting CD20-positive B-cell malignancies, and ADI-925, targeting GPC3-expressing solid tumors. Revenue generation is currently limited, as the company remains in the clinical development stage and does not have approved commercial products.
The company conducts its research and development activities primarily through its wholly owned subsidiary, Adicet Therapeutics, Inc., which manages laboratory research, preclinical development, and clinical trial execution. Manufacturing is supported through a combination of internal process development capabilities and external contract manufacturing organizations. Adicet Bio operates primarily in the United States, with additional research and corporate support functions in the United Kingdom; however, the full scope of international subsidiaries beyond publicly disclosed entities is data inconclusive based on available public sources.
Strategic Position & Investments
Adicet Bio’s strategic direction is focused on advancing its pipeline through clinical milestones while expanding the applicability of its γδ T cell platform across multiple cancer indications. Growth initiatives include progressing ongoing Phase 1 clinical trials, optimizing cell engineering technologies, and exploring combination strategies with existing oncology treatments. The company has emphasized disciplined capital allocation toward programs with clear translational and clinical differentiation.
The company has historically grown organically rather than through large-scale acquisitions, and no material acquisitions have been disclosed in recent public filings. Strategic investments are primarily internal, directed toward platform enhancement, manufacturing process development, and next-generation γδ T cell candidates. Adicet Bio continues to explore emerging technologies related to cell engineering and immuno-oncology, though specific future investments beyond its disclosed pipeline are not publicly detailed.
Geographic Footprint
Adicet Bio is headquartered in the United States, with its principal executive offices located in Boston, Massachusetts, a major biotechnology hub. The company’s primary research, clinical development, and corporate operations are concentrated in North America, where it conducts the majority of its clinical trials and collaborates with U.S.-based research institutions and service providers.
Internationally, Adicet Bio maintains a presence in Europe, primarily through operations in the United Kingdom, supporting research and development activities. While the company does not currently report commercial operations abroad, its clinical programs are designed for global applicability, and future international expansion is expected to align with regulatory progress and partnership opportunities.
Leadership & Governance
Adicet Bio is led by an executive team with experience in oncology drug development, cell therapy, and public biotechnology company management. The leadership emphasizes scientific rigor, clinical execution, and long-term value creation through platform-based innovation in immuno-oncology.
Key executives include:
- Chen Schor – President and Chief Executive Officer
- Brian Wong – Chief Financial Officer
- Nicholas Siciliano – Chief Medical Officer
- Scott Smith – Chief Scientific Officer
The company was co-founded by industry scientists and executives involved in early γδ T cell research and company formation; however, specific founder attribution varies across public disclosures, and comprehensive founder details are data inconclusive based on available public sources. The board of directors provides governance oversight consistent with U.S. public company standards, with committees overseeing audit, compensation, and corporate governance functions.